Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Peripheral Nervous System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Cardiotoxicity 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Trimetazidine × Clear all
NCT06459193 2025-03-30

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Minia University

Phase 1/2 Completed
60 enrolled

Hereditary Sensory and Autonomic Neuropathies, Peripheral Nervous System Diseases

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown
80 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡